Cargando…

Editorial: Overcoming drug relapse and therapy resistance in NSCLC

Detalles Bibliográficos
Autores principales:	Parakh, Sagun, Leong, Tracy L., Best, Sarah A., Poh, Ashleigh R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10282996/ https://www.ncbi.nlm.nih.gov/pubmed/37350939 http://dx.doi.org/10.3389/fonc.2023.1230475

Ejemplares similares

Multicellular Effects of STAT3 in Non-small Cell Lung Cancer: Mechanistic Insights and Therapeutic Opportunities
por: Parakh, Sagun, et al.
Publicado: (2021)

Antibody Drug Conjugates in Glioblastoma – Is There a Future for Them?
por: Parakh, Sagun, et al.
Publicado: (2021)

Editorial: Drug resistance in breast cancer – mechanisms and approaches to overcome chemoresistance
por: Raman, Dayanidhi, et al.
Publicado: (2023)

Preclinical Models for Acquired Resistance to Third-Generation EGFR Inhibitors in NSCLC: Functional Studies and Drug Combinations Used to Overcome Resistance
por: Mahfoudhi, Emna, et al.
Publicado: (2022)

Editorial: Targeting metabolism of cancer cells and host to overcome drug resistance: Preclinical and clinical studies
por: Wang, Lishun, et al.
Publicado: (2023)

Editorial: Emerging Biomarkers for NSCLC: Recent Advances in Diagnosis and Therapy
por: Malapelle, Umberto, et al.
Publicado: (2021)

Trials to Overcome Drug Resistance to EGFR and ALK Targeted Therapies – Past, Present, and Future
por: Spaans, Johanna N., et al.
Publicado: (2014)

Editorial: Immunotherapy for NSCLC with oncogenic driver variants
por: Du, Yijia, et al.
Publicado: (2022)

Overcoming the challenges of drug development in platinum-resistant ovarian cancer
por: Eskander, Ramez N., et al.
Publicado: (2023)

Case Report: Dacomitinib Overcomes Osimertinib Resistance in NSCLC Patient Harboring L718Q Mutation: A Case Report
por: Shen, Qian, et al.
Publicado: (2021)

Advances in targeting EGFR allosteric site as anti-NSCLC therapy to overcome the drug resistance
por: Maity, Swastika, et al.
Publicado: (2020)

Editorial: Strategies to overcome tumor evasion and resistance to immunotherapies by targeting immune suppressor cells
por: Saida, Yu, et al.
Publicado: (2023)

Editorial: Strategies in overcoming the chemoresistance in colorectal cancer
por: Vodenkova, Sona, et al.
Publicado: (2023)

Application of engineered extracellular vesicles to overcome drug resistance in cancer
por: Nonaka, Taichiro
Publicado: (2022)

Antibody–Drug Conjugates for Cancer Therapy
por: Hafeez, Umbreen, et al.
Publicado: (2020)

Real-world challenges in undertaking NTRK fusion testing in non-small cell lung cancer
por: Poh, Ashleigh, et al.
Publicado: (2023)

The Landscape of Immunotherapy Resistance in NSCLC
por: Frisone, Daniele, et al.
Publicado: (2022)

Editorial: Beyond chemotherapy and immunotherapy in thoracic malignancies: Overcoming resistance by tackling new molecular pathways
por: Mountzios, Giannis, et al.
Publicado: (2022)

Heterogeneity of tumour mutational burden in metastatic NSCLC demonstrated by endobronchial ultrasound sampling
por: Leong, Tracy L., et al.
Publicado: (2023)

Editorial: Overcoming the cell membrane to target intracellular oncoproteins
por: Brown, Christopher J., et al.
Publicado: (2023)

Rational Targeting of Cdc42 Overcomes Drug Resistance of Multiple Myeloma
por: Nguyen, Phuong, et al.
Publicado: (2019)

LAG3-PD-1 Combo Overcome the Disadvantage of Drug Resistance
por: Wei, Yiming, et al.
Publicado: (2022)

Editorial: Recent advances of drug resistance research in colorectal cancer therapy
por: Ye, Chenyang, et al.
Publicado: (2022)

Postoperative ctDNA detection predicts relapse but has limited effects in guiding adjuvant therapy in resectable stage I NSCLC
por: Wang, Bolin, et al.
Publicado: (2023)

Editorial: Challenges and opportunities of TKIs in the treatment of NSCLC patients with uncommon mutations
por: Su, Chunxia, et al.
Publicado: (2022)

Erratum: The landscape of immunotherapy resistance in NSCLC
Publicado: (2023)

Pharmacological STING Activation Is a Potential Alternative to Overcome Drug-Resistance in Melanoma
por: Chipurupalli, Sandhya, et al.
Publicado: (2020)

Overcoming therapeutic resistance to platinum-based drugs by targeting Epithelial–Mesenchymal transition
por: Duan, Xirui, et al.
Publicado: (2022)

Editorial: The impact of genetics on CRC therapy: from adaptive mutability to drug resistance
por: Crisafulli, Giovanni, et al.
Publicado: (2023)

Precision Medicine Approaches to Overcome Resistance to Therapy in Head and Neck Cancers
por: Ortiz-Cuaran, Sandra, et al.
Publicado: (2021)

Targeting O-GlcNAcylation to overcome resistance to anti-cancer therapies
por: Very, Ninon, et al.
Publicado: (2022)

Neoadjuvant Four-Drug Combination Therapy for NSCLC With EGFR Mutation Avoiding Total Pneumonectomy
por: Li, Jingpei, et al.
Publicado: (2020)

Editorial: Concomitant pathogenic mutations in oncogene-driven subgroups: when next generation biology meets targeted therapy in NSCLC
por: Malapelle, Umberto, et al.
Publicado: (2023)

Breast Cancer Stem-Like Cells in Drug Resistance: A Review of Mechanisms and Novel Therapeutic Strategies to Overcome Drug Resistance
por: Saha, Taniya, et al.
Publicado: (2022)

Overcoming Glucocorticoid Resistance in Acute Lymphoblastic Leukemia: Repurposed Drugs Can Improve the Protocol
por: Olivas-Aguirre, Miguel, et al.
Publicado: (2021)

Overcome Drug Resistance in Cholangiocarcinoma: New Insight Into Mechanisms and Refining the Preclinical Experiment Models
por: Zheng, Qingfan, et al.
Publicado: (2022)

Erratum: Neoadjuvant Four-Drug Combination Therapy for NSCLC With EGFR Mutation Avoiding Total Pneumonectomy
Publicado: (2020)

Antibody–Drug Conjugates for Cancer Therapy
por: Parslow, Adam C., et al.
Publicado: (2016)

Editorial: Microenvironment and therapy-resistance in leukemias
por: Friedmann, Rachel, et al.
Publicado: (2023)

Editorial: Adopting drug repurposing to overcome drug resistance in cancer
por: Shankar, Eswar, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_kqo9ie2pdphgo6bv90l6m68k02